ストックスクリーナーアプリを入手
35.36
2.75%
-1.00
Kodiak Sciences Inc (KOD) 最新ニュース
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1%Time to Sell? - MarketBeat
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com Nigeria
HC Wainwright Lowers Earnings Estimates for Kodiak Sciences - MarketBeat
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD - MarketBeat
KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58 - GuruFocus
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com Nigeria
HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Kodiak Sciences (KOD) Advances Late-Stage Trials Amid High Valua - GuruFocus
California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD - MarketBeat
Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell - MarketBeat
UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Kodiak Sciences (NASDAQ:KOD) Shares Gap DownTime to Sell? - MarketBeat
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodiak Sciences misses Q2 estimates, shares fall 5% By Investing.com - Investing.com Nigeria
Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Kodiak Sciences misses Q2 estimates, shares fall 5% - Investing.com
Kodiak Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kodiak Sciences Q2 net loss widens on higher R&D costs - TradingView
Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026 - TradingView
BRIEF-Kodiak Sciences Q2 Net Income USD -65.643 Million - TradingView
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results - Yahoo Finance
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema - BioPharma APAC
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema - TradingView
Kodiak Sciences Announces First Patients Enrolled In Global Phase 3 Alto Trial Of Ksi-501 In Patients With Diabetic Macular Edema - TradingView
Kodiak Sciences (KOD) Begins Enrollment for Phase 3 ALTO Trial T - GuruFocus
Kodiak Sciences enrolls first patients in phase 3 DME trial - Investing.com
Kodiak Sciences starts Phase 3 trial for KSI-50... - Pluang
Kodiak’s Eye Trial Tests Dosing Up to Six Months Apart - Stock Titan
Net margin % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Return on assets % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Kodiak Sciences, Inc. Statistics – HAM:K27 - TradingView
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema - marketscreener.com
Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed? - Sahm
The Manufacturers Life Insurance Company Acquires 29,121 Shares of Kodiak Sciences Inc. $KOD - MarketBeat
Kodiak completes enrollment in first KSI-101 trial cohort By Investing.com - Investing.com India
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Kodiak completes enrollment in first KSI-101 trial cohort - Investing.com
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 - Yahoo Finance
Kodiak's Trial Tests KSI-101 for Macular Edema Secondary to Inflammation - Stock Titan
Kodiak Sciences (KOD) Expected to Post Earnings on Wednesday - MarketBeat
KOD Maintained by JP Morgan -- Price Target Raised to $66.00 - GuruFocus
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Janus Henderson Group PLC Raises Stake in Kodiak Sciences Inc. $KOD - MarketBeat
Kodiak Sciences Inc Revenue Breakdown – NASDAQ:KOD - TradingView
57,400 Shares in Kodiak Sciences Inc. $KOD Acquired by Swiss National Bank - MarketBeat
KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock HigherNet Income Trends - vinanet.vn
Kodiak Sciences, Inc. Revenue Breakdown – BMV:KOD - TradingView
Kodiak Sciences Inc (KOD) Institutional Confidence - TradingKey
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):